SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies.
“Eric is a proven leader in building and maintaining exceptional company cultures and has an impressive track record in recruiting and retaining top talent in growing biopharmaceutical companies,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “We are thrilled to have him join our leadership team as we advance and expand our pipeline of promising oncology agents in the clinic.”
Mr. Schlezinger commented, “I am excited to join Nurix at this important phase of development with one of the broadest pipelines of targeted protein degradation and targeted protein elevation agents in the clinic. Nurix’s people are vital to the mission of bringing our novel therapies to patients, and I look forward to ensuring that we continue to attract, develop and retain top and diverse talent that equips Nurix for success.”
Most recently, Mr. Schlezinger was head of Human Resources at Adamas Pharmaceuticals, a commercial-stage pharmaceutical company, where he created structures to enhance leadership and employee development. Prior to Adamas, he was the senior vice president and head of Human Resources for Vir Biotechnology, where he developed the infrastructure, HR functions, and values that supported the organization’s rapid growth and transition to a public company. Earlier in his career, Mr. Schlezinger held leadership positions at Tessera Technologies, Dialogic Inc, Tumbleweed Communications and Roche Bioscience. He holds a juris doctorate from Washington University in St. Louis, and a bachelor’s degree from Dartmouth College.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the expected contributions Mr. Schlezinger will bring to Nurix, Nurix’s future plans and prospects, the planned timing of Nurix’s clinical trial programs for its drug candidates and the expansion of Nurix’s DELigase™ platform. Although Nurix believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Nurix’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including the risks and uncertainties described under the heading “Risk Factors” in documents Nurix files from time to time with the Securities and Exchange Commission (SEC) including Nurix’s Quarterly Report on Form 10-Q filed with the SEC on July 7, 2022, and other SEC filings. These forward-looking statements speak only as of the date of this press release, and Nurix undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law.
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors